Covid-19 Vaccine technologies: the need for speed
The world’s population is facing increased threats of disease. Whether it is Covid-19, cancer or influenza, the need for rapid development and deployment of cheaper, effective vaccines is on the rise. The traditional vaccine development pathway takes an average of 10 years. However, with around 5,000 deaths from Covid-19 per day, if we don’t move quickly and develop some effective vaccines or treatments, this virus will be even more catastrophic than it already is! The pandemic highlights the need for novel vaccine development and scaling strategies in order to bring solutions to market quicker.
In this webinar we will discuss the new methods and processes being used to accelerate vaccine development including mRNA vaccine processes that can potentially go from new pathogen to new vaccine candidate in weeks rather than years. We will also cover how CPI can demonstrate its experience and expertise in advanced vaccine manufacturing technologies to enable the production of cost-effective vaccines.
In this webinar you will learn about:
- Vaccines background and key players in the market
- Covid-19 vaccine technology overview
- Advantages and disadvantages of different types of Covid-19 vaccine technologies, covering mRNA, dna plasmid, protein subunit, viral vectored and inactivated virus vaccines
- Vaccine Development and Scale-up at CPI, including case studies of companies we have supported
Experts involved in vaccine development at CPI will join the Q&A panel.